ClinicalTrials.gg
TerminatedNCT03318861Updated Oct 19, 2023Results posted

Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma

A Phase 1 interventional study of KITE-585 and Cyclophosphamide in Relapsed/Refractory Multiple Myeloma, sponsored by Kite, A Gilead Company. Terminated at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-19.

Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated due to lack of efficacy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 171 studies testing cyclophosphamide in Multiple Myeloma — 15 open to participants now, 27 under way, 1 of them phase 3. Cyclophosphamide · Multiple Myeloma.

Enrollment
130th of 167
17 · median 41
Started
2017
with 14 others
Phase 1
35 of 171
3 open now
Registered
131st of 171
by date

Among the 171 studies testing cyclophosphamide in Multiple Myeloma, this one is the 130th largest by enrollment of the 167 interventional ones that give a count, is one of 15 that started in 2017, is one of 35 in phase 1, and was the 131st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 171 studies testing cyclophosphamide in Multiple Myeloma are open now, in 4 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies testing cyclophosphamide in Multiple Myeloma, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the safety and tolerability of KITE-585, an autologous engineered chimeric antigen receptor (CAR) T-cell product targeting a protein commonly found on myeloma cells called B-cell maturation antigen (BCMA), as measured by the incidence of dose-limiting toxicities (DLTs). Participants will be given a 3 day course of conditioning chemotherapy followed by a single infusion of KITE-585.

Read the detailed description

Participants with relapsed/refractory multiple myeloma can participate if all eligibility criteria are met. Tests required to determine eligibility include disease assessments, a physical exam, ECG and echocardiogram of the heart, brain MRI, and blood draws. Eligible participants have white blood cells collected by leukapheresis. These cells are genetically modified to make the experimental treatment KITE-585. Participants receive conditioning chemotherapy prior to the KITE-585 infusion. After the KITE-585 infusion, participants will be followed for side effects and effect of KITE-585 on their myeloma. Study procedures may be performed while hospitalized and/or in the outpatient setting. Participants who received an infusion of KITE-585 will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968

03

Conditions studied

  • Relapsed/Refractory Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Measurable myeloma as defined by the International Myeloma Working Group (IMWG) Consensus Criteria following treatment with at least 3 including with both a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or progressive myeloma that is refractory to a regimen containing both a PI and an IMiD.
  2. (ECOG) performance status of 0 or 1
  3. Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function defined as:

    • (ANC) ≥ 1,000/µL
    • count ≥ 75,000/µL
    • Absolute lymphocyte count ≥ 100/µL
    • above limits set in the protocol for each cohort
    • Normal cardiac function as assessed by (ECG) and echocardiogram
    • Baseline oxygen saturation > 92% on room air and no pleural effusion

Key Exclusion Criteria:

  1. Plasma cell leukemia
  2. Non-secretory multiple myeloma
  3. History of Central nervous system (CNS) involvement by multiple myeloma
  4. Prior CAR therapy or other genetically modified T cells
  5. Inadequate washout from prior therapy
  6. stem cell transplant within 6 weeks before enrollment or any history of allogenic transplant
  7. History of active disease
  8. History of deep vein thrombosis or pulmonary embolism requiring systemic anticoagulation within 6 months before enrollment
  9. Recent history of other (non multiple myeloma) cancer
  10. Active viral, fungal, bacterial or other infection

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Dose Escalation: 3 x 10^7 KITE-585

    Participants with relapsed/refractory multiple myeloma (RRMM), will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day intravenous (IV) infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10\^7 autologous anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.

    Genetic: KITE-585 · Drug: Cyclophosphamide · Drug: Fludarabine

  • Experimental
    Dose Escalation: 1 x 10^8 KITE-585

    Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10\^8 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.

    Genetic: KITE-585 · Drug: Cyclophosphamide · Drug: Fludarabine

  • Experimental
    Dose Escalation: 3 x 10^8 KITE-585

    Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10\^8 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.

    Genetic: KITE-585 · Drug: Cyclophosphamide · Drug: Fludarabine

  • Experimental
    Dose Escalation: 1 x 10^9 KITE-585

    Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10\^9 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.

    Genetic: KITE-585 · Drug: Cyclophosphamide · Drug: Fludarabine

  • Experimental
    Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585

    RRMM participants with moderate renal impairment (creatinine clearance 30 to 59 mL/min \[Grade 2 chronic kidney disease\]) will receive a conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\^2/day and fludarabine 24 mg/m\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a tolerable dose of 3 x 10\^7 autologous anti-BCMA CAR T cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants then had a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.

    Genetic: KITE-585 · Drug: Cyclophosphamide · Drug: Fludarabine

Interventions

  • GeneticKITE-585

    A single infusion of KITE-585 autologous anti-BCMA CAR T cells

  • Administered intravenously

  • Administered intravenously

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)

    A DLT is a KITE-585-related event with onset in the first 28 days following infusion. DLTs are defined by events and duration of events, including: * Any duration: Grade (GR) 4 cytokine release syndrome (CRS), KITE-585-related GR 5 adverse events (AE) and GR 4 nonhematologic AE with the exceptions of fever, nausea, hepatic toxicity that resolves to GR 3 or better in ≤ 72 hours, hypogammaglobulinemia, tumor lysis syndrome, acute renal toxicity requiring dialysis for ≤ 7 days, intubation for airway protection for ≤ 7 days and AE resolves to ≤ GR 1 within 2 weeks and baseline within 4 weeks * ≥ 72 hours: GR 3 CRS and GR 3 nonhematologic AE with the exceptions of fever, nausea, hepatic toxicity that resolves to GR 2 or better in ≤ 14 days, hypogammaglobulinemia and tumor lysis syndrome * ≥ 30 days: GR 4 hematologic AE with the exceptions of cytopenias attributable to ongoing or recurrent multiple myeloma

    Time frame: From KITE-585 infusion until 28 days after KITE-585 infusion

Secondary outcomes

  1. Objective Response Rate (ORR) as Determined by Study Investigators According to the International Myeloma Working Group (IMWG) Consensus Panel 1 Criteria

    ORR: Percentage of participants who achieved a stringent CR (sCR), complete response (CR), partial response (PR), or very good PR (VGPR), as determined by IMWG Consensus Panel 1 Criteria. sCR: CR+normal free light chain (FLC) ratio, no clonal cells in BM by immunohistochemistry or immunofluorescence; CR: negative immunofixation (IFX) on serum and urine, no soft tissue plasmacytomas (STP), \<5% plasma cells in bone marrow (BM); PR: ≥50% decrease of serum M-protein + 24hr urinary M-protein decrease by ≥90% or \<200 mg/24hr. If unmeasurable serum and urine M-protein; and serum-free light assay; requires ≥ 50% decrease in the difference between involved and uninvolved FLC levels / ≥ 50% reduction in plasma cells (PC), provided baseline BM PC percentage was ≥ 30%, respectively. If present at baseline, ≥ 50% reduction in the size of STP is also required; VGPR: serum and urine M-protein detected by IFX but not electrophoresis, \>90% in serum M-protein+urine, M-protein level \<100 mg/24hr.

    Time frame: From KITE-585 infusion to the earlier date of data cutoff and first administration of other anti-cancer therapies including stem cell transplant (maximum: 17.6 months)

  2. Progression Free Survival (PFS) as Determined by Study Investigators According to the IMWG Consensus Panel 1

    PFS: Interval from first study drug dose date to the earlier of first documentation of definitive progressive disease (PD) per IMWG Consensus Panel 1 Criteria or death from any cause. PD: an increase of 25% from the lowest response value in 1 of the following: Serum and urine M-protein (absolute increase ≥ 0.5 g/dL and ≥ 200 mg/24 hours, respectively); In participants without measurable serum and urine M-protein levels, the difference between involved and uninvolved FLC levels (absolute increase \> 10 mg/dL); In participants without measurable serum and urine M-protein and without measurable disease by FLC levels, bone marrow PC percentage (absolute percentage ≥ 10%). Definite development of new bone lesions or STP or definite increase in the size of existing bone lesions or STPs; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder. Analysis was done using Kaplan-Meier (KM) estimate.

    Time frame: From KITE-585 infusion to the earlier date of data cutoff and first administration of other anti-cancer therapies including stem cell transplant (maximum: 17.6 months)

  3. Overall Survival (OS)

    Overall survival is defined as the time from the first dose date of study drug to the date of death from any cause. Analysis was done using KM estimate. Participants who have not died by the analysis data cutoff date were censored at their last date known to be alive or cutoff date, whichever is earlier.

    Time frame: From KITE-585 infusion to date of data cutoff (maximum: 17.6 months)

  4. Percentage of Participants Experiencing Treatment-Emergent Adverse Events

    Time frame: Enrollment through 24 months after treatment with KITE-585 or up to disease progression or initiation of another anti-cancer therapy, whichever occurs first (maximum: 2.9 months)

  5. Percentage of Participants Experiencing Clinically Significant Laboratory Abnormalities

    Clinically significant laboratory abnormalities were defined as per investigator's discretion.

    Time frame: Enrollment through 24 months after treatment with KITE-585 or up to disease progression or initiation of another anti-cancer therapy, whichever occurs first (maximum: 2.9 months)

  6. Duration of Response (DOR) as Determined by Study Investigators According to the IMWG Consensus Panel 1

    DOR is defined for participants who experience an objective response and is defined as the time from the date of their first objective response (which is subsequently confirmed) to PD per IMWG Consensus Panel 1 Criteria or death from any cause, whichever is earlier. Objective response is defined in Outcome measure 2.

    Time frame: From first response to the earlier date of data cutoff and first administration of other anti-cancer therapies including stem cell transplant (maximum: 17.6 months)

  7. Time to Next Treatment (TTNT)

    TTNT is defined as the length of time between the date of KITE-585 infusion to the date of initiation of the next therapy or death due to any cause, whichever is earlier.

    Time frame: From KITE-585 infusion to the earlier date of data cutoff and first administration of other anti-cancer therapies including stem cell transplant (maximum: 17.6 months)

07

Results

Posted May 26, 2020

Participant flow

Participants were enrolled at study sites in the United States.

Participant flow — Overall Study
MilestoneDose Escalation: 3 x 10^7 KITE-585Dose Escalation: 1 x 10^8 KITE-585Dose Escalation: 3 x 10^8 KITE-585Dose Escalation: 1 x 10^9 KITE-585Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585
Started34343
Completed00000
Not completed34343
Withdrew: Death23322
Withdrew: Enrolled but never treated01011
Withdrew: Informed consent withdraw00010
Withdrew: Withdrawal of consent from further follow-up10000

Outcome measures

PrimaryPercentage of Participants Experiencing Dose Limiting Toxicities (DLTs)

A DLT is a KITE-585-related event with onset in the first 28 days following infusion. DLTs are defined by events and duration of events, including: * Any duration: Grade (GR) 4 cytokine release syndrome (CRS), KITE-585-related GR 5 adverse events (AE) and GR 4 nonhematologic AE with the exceptions of fever, nausea, hepatic toxicity that resolves to GR 3 or better in ≤ 72 hours, hypogammaglobulinemia, tumor lysis syndrome, acute renal toxicity requiring dialysis for ≤ 7 days, intubation for airway protection for ≤ 7 days and AE resolves to ≤ GR 1 within 2 weeks and baseline within 4 weeks * ≥ 72 hours: GR 3 CRS and GR 3 nonhematologic AE with the exceptions of fever, nausea, hepatic toxicity that resolves to GR 2 or better in ≤ 14 days, hypogammaglobulinemia and tumor lysis syndrome * ≥ 30 days: GR 4 hematologic AE with the exceptions of cytopenias attributable to ongoing or recurrent multiple myeloma

Time frame:
From KITE-585 infusion until 28 days after KITE-585 infusion
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)
percentage of participantsDose Escalation: 3 x 10^7 KITE-585Dose Escalation: 1 x 10^8 KITE-585Dose Escalation: 3 x 10^8 KITE-585Dose Escalation: 1 x 10^9 KITE-585
Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)0000
SecondaryObjective Response Rate (ORR) as Determined by Study Investigators According to the International Myeloma Working Group (IMWG) Consensus Panel 1 Criteria

ORR: Percentage of participants who achieved a stringent CR (sCR), complete response (CR), partial response (PR), or very good PR (VGPR), as determined by IMWG Consensus Panel 1 Criteria. sCR: CR+normal free light chain (FLC) ratio, no clonal cells in BM by immunohistochemistry or immunofluorescence; CR: negative immunofixation (IFX) on serum and urine, no soft tissue plasmacytomas (STP), \<5% plasma cells in bone marrow (BM); PR: ≥50% decrease of serum M-protein + 24hr urinary M-protein decrease by ≥90% or \<200 mg/24hr. If unmeasurable serum and urine M-protein; and serum-free light assay; requires ≥ 50% decrease in the difference between involved and uninvolved FLC levels / ≥ 50% reduction in plasma cells (PC), provided baseline BM PC percentage was ≥ 30%, respectively. If present at baseline, ≥ 50% reduction in the size of STP is also required; VGPR: serum and urine M-protein detected by IFX but not electrophoresis, \>90% in serum M-protein+urine, M-protein level \<100 mg/24hr.

Time frame:
From KITE-585 infusion to the earlier date of data cutoff and first administration of other anti-cancer therapies including stem cell transplant (maximum: 17.6 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) as Determined by Study Investigators According to the International Myeloma Working Group (IMWG) Consensus Panel 1 Criteria
percentage of participantsDose Escalation: 3 x 10^7 KITE-585Dose Escalation: 1 x 10^8 KITE-585Dose Escalation: 3 x 10^8 KITE-585Dose Escalation: 1 x 10^9 KITE-585Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585
Objective Response Rate (ORR) as Determined by Study Investigators According to the International Myeloma Working Group (IMWG) Consensus Panel 1 Criteria33.30000
SecondaryProgression Free Survival (PFS) as Determined by Study Investigators According to the IMWG Consensus Panel 1

PFS: Interval from first study drug dose date to the earlier of first documentation of definitive progressive disease (PD) per IMWG Consensus Panel 1 Criteria or death from any cause. PD: an increase of 25% from the lowest response value in 1 of the following: Serum and urine M-protein (absolute increase ≥ 0.5 g/dL and ≥ 200 mg/24 hours, respectively); In participants without measurable serum and urine M-protein levels, the difference between involved and uninvolved FLC levels (absolute increase \> 10 mg/dL); In participants without measurable serum and urine M-protein and without measurable disease by FLC levels, bone marrow PC percentage (absolute percentage ≥ 10%). Definite development of new bone lesions or STP or definite increase in the size of existing bone lesions or STPs; Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder. Analysis was done using Kaplan-Meier (KM) estimate.

Time frame:
From KITE-585 infusion to the earlier date of data cutoff and first administration of other anti-cancer therapies including stem cell transplant (maximum: 17.6 months)
Reported as:
Median · months
Progression Free Survival (PFS) as Determined by Study Investigators According to the IMWG Consensus Panel 1
monthsDose Escalation: 3 x 10^7 KITE-585Dose Escalation: 1 x 10^8 KITE-585Dose Escalation: 3 x 10^8 KITE-585Dose Escalation: 1 x 10^9 KITE-585Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585
Progression Free Survival (PFS) as Determined by Study Investigators According to the IMWG Consensus Panel 11.1 (0.5 to 3.2)1.0 (0.9 to 1.0)0.8 (0.5 to 1.0)1.0 (0.9 to 1.0)NA (2.0 to NA)
SecondaryOverall Survival (OS)

Overall survival is defined as the time from the first dose date of study drug to the date of death from any cause. Analysis was done using KM estimate. Participants who have not died by the analysis data cutoff date were censored at their last date known to be alive or cutoff date, whichever is earlier.

Time frame:
From KITE-585 infusion to date of data cutoff (maximum: 17.6 months)
Reported as:
Median · months
Overall Survival (OS)
monthsDose Escalation: 3 x 10^7 KITE-585Dose Escalation: 1 x 10^8 KITE-585Dose Escalation: 3 x 10^8 KITE-585Dose Escalation: 1 x 10^9 KITE-585Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585
Overall Survival (OS)NA (11.1 to NA)5.1 (3.0 to NA)6.9 (3.2 to NA)NA (5.5 to NA)12.2 (NA to NA)
SecondaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events
Time frame:
Enrollment through 24 months after treatment with KITE-585 or up to disease progression or initiation of another anti-cancer therapy, whichever occurs first (maximum: 2.9 months)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
percentage of participantsDose Escalation: 3 x 10^7 KITE-585Dose Escalation: 1 x 10^8 KITE-585Dose Escalation: 3 x 10^8 KITE-585Dose Escalation: 1 x 10^9 KITE-585Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585
Percentage of Participants Experiencing Treatment-Emergent Adverse Events100.0100.0100.0100.0100.0
SecondaryPercentage of Participants Experiencing Clinically Significant Laboratory Abnormalities

Clinically significant laboratory abnormalities were defined as per investigator's discretion.

Time frame:
Enrollment through 24 months after treatment with KITE-585 or up to disease progression or initiation of another anti-cancer therapy, whichever occurs first (maximum: 2.9 months)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Clinically Significant Laboratory Abnormalities
percentage of participantsDose Escalation: 3 x 10^7 KITE-585Dose Escalation: 1 x 10^8 KITE-585Dose Escalation: 3 x 10^8 KITE-585Dose Escalation: 1 x 10^9 KITE-585Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585
Percentage of Participants Experiencing Clinically Significant Laboratory Abnormalities00000
SecondaryDuration of Response (DOR) as Determined by Study Investigators According to the IMWG Consensus Panel 1

DOR is defined for participants who experience an objective response and is defined as the time from the date of their first objective response (which is subsequently confirmed) to PD per IMWG Consensus Panel 1 Criteria or death from any cause, whichever is earlier. Objective response is defined in Outcome measure 2.

Time frame:
From first response to the earlier date of data cutoff and first administration of other anti-cancer therapies including stem cell transplant (maximum: 17.6 months)
Reported as:
Number · months
Duration of Response (DOR) as Determined by Study Investigators According to the IMWG Consensus Panel 1
monthsDose Escalation: 3 x 10^7 KITE-585Dose Escalation: 1 x 10^8 KITE-585Dose Escalation: 3 x 10^8 KITE-585Dose Escalation: 1 x 10^9 KITE-585Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585
Duration of Response (DOR) as Determined by Study Investigators According to the IMWG Consensus Panel 1NA————
SecondaryTime to Next Treatment (TTNT)

TTNT is defined as the length of time between the date of KITE-585 infusion to the date of initiation of the next therapy or death due to any cause, whichever is earlier.

Time frame:
From KITE-585 infusion to the earlier date of data cutoff and first administration of other anti-cancer therapies including stem cell transplant (maximum: 17.6 months)
Reported as:
Number · months
Time to Next Treatment (TTNT)
monthsDose Escalation: 3 x 10^7 KITE-585Dose Escalation: 1 x 10^8 KITE-585Dose Escalation: 3 x 10^8 KITE-585Dose Escalation: 1 x 10^9 KITE-585Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585
Time to Next Treatment (TTNT)NANANANANA

Adverse events

Collected over Adverse Events: Enrollment through 24 months after treatment with KITE-585 or up to disease progression or initiation of another anti-cancer therapy, whichever occurs first. (maximum: 2.9 months) All-Cause Mortality: Enrollment up to 57.6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Escalation: 3 x 10^7 KITE-5852/3 (66.7%)0/3 (0%)3/3 (100%)
Dose Escalation: 1 x 10^8 KITE-5854/4 (100%)0/3 (0%)3/3 (100%)
Dose Escalation: 3 x 10^8 KITE-5853/3 (100%)1/3 (33.3%)3/3 (100%)
Dose Escalation: 1 x 10^9 KITE-5853/4 (75%)0/3 (0%)3/3 (100%)
Dose Expansion (Renal Impairment): 3 x 10^7 KITE-5853/3 (100%)0/2 (0%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventDose Escalation: 3 x 10^7 KITE-585Dose Escalation: 1 x 10^8 KITE-585Dose Escalation: 3 x 10^8 KITE-585Dose Escalation: 1 x 10^9 KITE-585Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585
Chest painGeneral disorders0/30/31/30/30/2
HypoxiaRespiratory, thoracic and mediastinal disorders0/30/31/30/30/2
Most frequent other events
Showing 10 of 62
Most frequent other events
EventDose Escalation: 3 x 10^7 KITE-585Dose Escalation: 1 x 10^8 KITE-585Dose Escalation: 3 x 10^8 KITE-585Dose Escalation: 1 x 10^9 KITE-585Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585
AnaemiaBlood and lymphatic system disorders1/32/32/32/32/2
NauseaGastrointestinal disorders0/31/33/31/31/2
Neutrophil count decreasedInvestigations2/31/31/33/30/2
HeadacheNervous system disorders0/31/31/31/32/2
NeutropeniaBlood and lymphatic system disorders0/32/32/30/31/2
ThrombocytopeniaBlood and lymphatic system disorders0/31/32/30/31/2
ConstipationGastrointestinal disorders0/31/32/30/30/2
FatigueGeneral disorders0/31/31/32/31/2
White blood cell count decreasedInvestigations2/32/31/31/30/2
HypomagnesaemiaMetabolism and nutrition disorders0/31/32/32/30/2

Baseline characteristics

The Full Analysis Set included all participants who were enrolled in the study.

Age, Categorical
Age, Categorical(Participants)Dose Escalation: 3 x 10^7 KITE-585Dose Escalation: 1 x 10^8 KITE-585Dose Escalation: 3 x 10^8 KITE-585Dose Escalation: 1 x 10^9 KITE-585Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585Total
<=18 years000000
Between 18 and 65 years3324214
>=65 years011013
Age, Continuous
Age, Continuous(years)Dose Escalation: 3 x 10^7 KITE-585Dose Escalation: 1 x 10^8 KITE-585Dose Escalation: 3 x 10^8 KITE-585Dose Escalation: 1 x 10^9 KITE-585Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585Total
Mean52.3 (50 to 56)59.8 (49 to 71)59.3 (49 to 67)54.3 (47 to 58)56.3 (47 to 65)56.5 (47 to 71)
Sex: Female, Male
Sex: Female, Male(Participants)Dose Escalation: 3 x 10^7 KITE-585Dose Escalation: 1 x 10^8 KITE-585Dose Escalation: 3 x 10^8 KITE-585Dose Escalation: 1 x 10^9 KITE-585Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585Total
Female012227
Male3312110
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dose Escalation: 3 x 10^7 KITE-585Dose Escalation: 1 x 10^8 KITE-585Dose Escalation: 3 x 10^8 KITE-585Dose Escalation: 1 x 10^9 KITE-585Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585Total
Hispanic or Latino000011
Not Hispanic or Latino3434216
Unknown or Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dose Escalation: 3 x 10^7 KITE-585Dose Escalation: 1 x 10^8 KITE-585Dose Escalation: 3 x 10^8 KITE-585Dose Escalation: 1 x 10^9 KITE-585Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585Total
White3313313
Black or African American011103
Other001001
08

Study locations

9 sites
  • David Geffen School of Medicine at UCLA
    Los Angeles, California 90095, United States
  • H. Lee Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Winship Cancer Institute, Emory University
    Atlanta, Georgia 30322, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02114, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Cornell RF, Bishop MR, Kumar S, Giralt SA, Nooka AK, Larson SM, Locke FL, Raje NS, Lei L, Dong J, Le Gall JB, Rossi JM, Orlowski RZ. A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. Am J Cancer Res. 2021 Jun 15;11(6):3285-3293. eCollection 2021. PubMed 34249462 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Dec 2018, 13 months.

Results were first posted in May 2020, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2017
First posted
Oct 24, 2017
StartActual
Oct 20, 2017
Primary completionActual
Dec 17, 2018
CompletionActual
Sep 16, 2022
Results first posted
May 26, 2020
Last update
Oct 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03318861
Responsible party
Sponsor
First posted
Oct 24, 2017
Start date
Oct 20, 2017
Primary completion
Dec 17, 2018
Completion
Sep 16, 2022
Results posted
May 26, 2020
Last update
Oct 19, 2023

Study contacts

Kite Study Director
study director · Kite, A Gilead Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Fludarabine

Start the discussion